Skip to main content
Premium Trial:

Request an Annual Quote

Enigma Supplies POC Chlamydia Dx for UK Screening Program

NEW YORK (GenomeWeb News) — Enigma Diagnostics said today it has developed a DNA assay for the UK healthcare system to screen for Chlamydia trachomatis, the most common treatable sexually transmitted disease in that country.
Enigma, based in Porton Down, UK, said its assay, reagents, and instrumentation can detect C. trachomatis DNA from urine and or swab samples “in a matter of minutes.” The test is based on Enigma's fully automated diagnostics platform, which uses real-time PCR to detect bacterial target DNA in samples.
Enigma said the Defense Science and Technology Laboratory commissioned the company to create a swift, point-of-care diagnostic for the UK National Chlamydia Screening Program.
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.